International AIDS Society Conference

July 17-20, 2011 - Rome, Italy

Back IAS 2011

IAS 2011: Once-daily Elvitegravir Matches Twice-daily Raltegravir

The experimental HIV integrase inhibitor elvitegravir works as well as raltegravir (Isentress) for treatment-experienced people with extensive drug resistance, and was well-tolerated overall, according to data presented at the International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) this week in Rome. alt

Read more:

IAS 2011: The Proof is Here: HIV Treatment is HIV Prevention

Antiretroviral treatment was shown to prevent HIV infection in the large, randomized trial HPTN 052 trial, reducing risk by 96%, researchers reported at IAS 2011 this week in Rome.

"There is a clinical benefit for the patient and a dramatic, nearly 100% reduction in transmission," said lead investigator Myron Cohen. "We can't get much better." alt

Read more:

IAS 2011: Stakeholders Call for HIV Cure Research

Over the past few years a cure for HIV has again become a goal of HIV/AIDS research. The International AIDS Society is a leading proponent of greater investment in cure-related science. alt

Read more:

IAS 2011: Coronary Artery Calcification Linked to Bone Loss

Coronary artery calcification is associated with and low femoral bone mineral density (BMD), but no such link found with lumbar spine BMD, researchers reported at IAS 2011 in Rome.

alt

Read more:

IAS 2011: HIV Treatment as Prevention: HPTN 052 Offers Proof [VIDEO]

HPTN 052 lead investigator Myron Cohen talked to Paul Dalton from HIVandHepatitis.com about the study's findings and their significance. alt

Read more: